INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	MODIFIED PTO/SB/08a (09-08)
Application Number	10/594,127
Filing Date	September 25, 2006
First Named Inventor	Akio SUGIHARA
Art Unit	1625
Examiner Name	Niloofar RAHMANI
Attornov Dooket Number	007201

	U.S. PATENTS							
Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1							

	U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1							

ĺ	FOREIGN PATENT DOCUMENTS								
	Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
I		1	1 714 965	EP	A1	2006-10-25	Astellas Pharma Inc.		
I		2	1 726 304	EP	A1	2006-11-29	Astellas Pharma Inc.		

	NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials* Cite No Cite No Cite No Dishibiter, city, and/or country where published.						
	1	MEALY N., et al., "Treatment of Urinary Incontinence Muscarinic M3 Antagonist", Drugs of the Future, PROUS SCIENCE, Vol. 24, No. 8, January 1, 1999, pages 871-874, XP001061585.				
	2	HEDGE Sharath S., "Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies", Current Opinion in Investigational Drugs, Vol. 5, No. 1, January 1, 2004, pages 40- 49, XP008061336.				
	3	"VESIcare", www.rxlist.com/vesicare-drug.htm, page 1, XP002500528.				
	4	"Amorphous Solids: Implications for Solubility and Stability", www.ssci- inc.com/information/RecentPublications/ApplicationNotes/Amorphous SolidsImplications/tabid/142/Default. aspx, 2003, pages 1-3, XPO02S005273.				
	5	Supplementary European Search Report dated November 10, 2008				

EXAMINER SIGNATURE					
Examiner Signature		Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precode the serial number of the patent document. 4 Kind of document by the appropriets exprised symbols as indicated on the document under VIPO Standard ST 1.6 if possible 5. Applicant is to Spece a check mark English language stranslation is attached.